Q2 2018 EPS Estimates for Eagle Pharmaceuticals Increased by Analyst (EGRX)

Eagle Pharmaceuticals (NASDAQ:EGRX) – Equities research analysts at William Blair increased their Q2 2018 earnings per share (EPS) estimates for shares of Eagle Pharmaceuticals in a research note issued on Monday, April 16th. William Blair analyst T. Lugo now anticipates that the specialty pharmaceutical company will post earnings per share of $0.77 for the quarter, up from their previous estimate of $0.73. William Blair also issued estimates for Eagle Pharmaceuticals’ FY2018 earnings at $2.44 EPS and FY2019 earnings at $2.68 EPS.

How to Become a New Pot Stock Millionaire

Eagle Pharmaceuticals (NASDAQ:EGRX) last posted its quarterly earnings results on Monday, February 26th. The specialty pharmaceutical company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.00 by ($0.16). The company had revenue of $46.80 million during the quarter, compared to analyst estimates of $53.65 million. Eagle Pharmaceuticals had a net margin of 21.94% and a return on equity of 34.16%. Eagle Pharmaceuticals’s revenue for the quarter was down 42.3% on a year-over-year basis. During the same period in the prior year, the business earned $3.52 EPS.

A number of other equities research analysts have also issued reports on the company. Mizuho reaffirmed an “underperform” rating and issued a $40.00 price target (up previously from $37.00) on shares of Eagle Pharmaceuticals in a research report on Wednesday, March 21st. BidaskClub lowered Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 18th. Royal Bank of Canada set a $71.00 price target on Eagle Pharmaceuticals and gave the company a “buy” rating in a research report on Monday, February 26th. Zacks Investment Research lowered Eagle Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 9th. Finally, Piper Jaffray reaffirmed a “buy” rating and issued a $79.00 price target on shares of Eagle Pharmaceuticals in a research report on Tuesday, January 30th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $63.33.

EGRX stock opened at $53.76 on Tuesday. The company has a current ratio of 3.99, a quick ratio of 3.88 and a debt-to-equity ratio of 0.24. The stock has a market capitalization of $778.92, a price-to-earnings ratio of 15.95 and a beta of 1.38. Eagle Pharmaceuticals has a 1 year low of $45.05 and a 1 year high of $97.15.

In other news, Director Sander A. Flaum sold 2,340 shares of the firm’s stock in a transaction dated Tuesday, March 6th. The stock was sold at an average price of $53.94, for a total transaction of $126,219.60. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. 19.50% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Legal & General Group Plc grew its stake in Eagle Pharmaceuticals by 9.5% during the 3rd quarter. Legal & General Group Plc now owns 16,403 shares of the specialty pharmaceutical company’s stock worth $978,000 after buying an additional 1,419 shares during the last quarter. SG Americas Securities LLC grew its stake in Eagle Pharmaceuticals by 60.8% during the 3rd quarter. SG Americas Securities LLC now owns 4,511 shares of the specialty pharmaceutical company’s stock worth $269,000 after buying an additional 1,706 shares during the last quarter. Municipal Employees Retirement System of Michigan grew its stake in Eagle Pharmaceuticals by 57.6% during the 4th quarter. Municipal Employees Retirement System of Michigan now owns 5,060 shares of the specialty pharmaceutical company’s stock worth $270,000 after buying an additional 1,850 shares during the last quarter. Rhumbline Advisers grew its stake in Eagle Pharmaceuticals by 14.2% during the 4th quarter. Rhumbline Advisers now owns 19,501 shares of the specialty pharmaceutical company’s stock worth $1,042,000 after buying an additional 2,425 shares during the last quarter. Finally, Cubist Systematic Strategies LLC grew its stake in Eagle Pharmaceuticals by 77.0% during the 3rd quarter. Cubist Systematic Strategies LLC now owns 6,554 shares of the specialty pharmaceutical company’s stock worth $391,000 after buying an additional 2,852 shares during the last quarter.

COPYRIGHT VIOLATION NOTICE: “Q2 2018 EPS Estimates for Eagle Pharmaceuticals Increased by Analyst (EGRX)” was first posted by Week Herald and is the property of of Week Herald. If you are viewing this piece of content on another domain, it was stolen and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece of content can be accessed at https://weekherald.com/2018/04/18/q2-2018-eps-estimates-for-eagle-pharmaceuticals-increased-by-analyst-egrx.html.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply